NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device

Recruiting

Conditions: Bladder Cancer

Interventions: Device: modified resectoscope
Procedure: TURBT

First Posted Date: 2020-01-22

Last Posted Date: 2025-05-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 25

Registration Number: NCT04235764

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies

Phase 1

Recruiting

Conditions: Urothelial Cancer
Genitourinary Cancer
Urogenital Neoplasms
Bladder Cancer
Urogenital Cancer

Interventions: Drug: PDS01ADC
Radiation: Stereotactic body radiation therapy (SBRT)
Drug: M7824

First Posted Date: 2020-01-22

Last Posted Date: 2025-06-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 100

Registration Number: NCT04235777

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors

Phase 1

Active, not recruiting

Conditions: Metastatic Digestive System Neuroendocrine Neoplasm
Metastatic Neuroendocrine Tumor

Interventions: Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Lutetium Lu 177 Dotatate
Procedure: Magnetic Resonance Imaging
Drug: Triapine

First Posted Date: 2020-01-21

Last Posted Date: 2025-03-18

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 33

Registration Number: NCT04234568

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
🇺🇸
Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States

and more 8 locations

Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

Phase 1

Recruiting

Conditions: Metastatic Pancreatic Cancer
Pediatric Solid Tumor
Advanced Breast Cancer
Malignant Peripheral Nerve Sheath Tumor
Colorectal Neoplasms
Advanced Solid Tumors

Interventions: Drug: Metarrestin

First Posted Date: 2020-01-10

Last Posted Date: 2025-06-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 98

Registration Number: NCT04222413

Locations: 🇺🇸
University of Kansas, Fairway, Kansas, United States
🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia

Phase 2

Active, not recruiting

Conditions: Acute Myeloid Leukemia
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Acute Myeloid Leukemia Post Cytotoxic Therapy
Secondary Acute Myeloid Leukemia

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Procedure: Computed Tomography
Drug: Cytarabine
Drug: Daunorubicin Hydrochloride
Procedure: Echocardiography Test
Procedure: Hematopoietic Cell Transplantation
Drug: Idarubicin Hydrochloride
Procedure: Multigated Acquisition Scan
Biological: Pembrolizumab
Procedure: Punch Biopsy

First Posted Date: 2020-01-02

Last Posted Date: 2025-04-18

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 48

Registration Number: NCT04214249

Locations: 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸
UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States
🇺🇸
Wake Forest Baptist Health - Wilkes Medical Center, Wilkesboro, North Carolina, United States

and more 7 locations

Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer

Phase 1

Active, not recruiting

Conditions: Lung Non-Small Cell Squamous Carcinoma
Stage IV Lung Cancer AJCC v8

Interventions: Drug: Berzosertib
Procedure: Biospecimen Collection
Drug: Carboplatin
Procedure: Computed Tomography
Drug: Gemcitabine Hydrochloride
Procedure: Magnetic Resonance Imaging
Biological: Pembrolizumab

First Posted Date: 2020-01-02

Last Posted Date: 2024-07-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 12

Registration Number: NCT04216316

Locations: 🇺🇸
UM Sylvester Comprehensive Cancer Center at Aventura, Aventura, Florida, United States
🇺🇸
Los Angeles General Medical Center, Los Angeles, California, United States
🇺🇸
USC Norris Oncology/Hematology-Newport Beach, Newport Beach, California, United States

and more 31 locations

Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer

Phase 3

Active, not recruiting

Conditions: Stage I Lung Cancer AJCC v8
Lung Non-Small Cell Carcinoma
Stage II Lung Cancer AJCC v8

Interventions: Drug: Atezolizumab
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Other: Fludeoxyglucose F-18
Procedure: Positron Emission Tomography
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Radiation: Stereotactic Body Radiation Therapy

First Posted Date: 2020-01-02

Last Posted Date: 2025-03-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 480

Registration Number: NCT04214262

Locations: 🇺🇸
Aurora West Allis Medical Center, West Allis, Wisconsin, United States
🇺🇸
Marshfield Medical Center - Weston, Weston, Wisconsin, United States
🇺🇸
Aspirus Cancer Care - Wisconsin Rapids, Wisconsin Rapids, Wisconsin, United States

and more 388 locations

A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial

Phase 2

Active, not recruiting

Conditions: Bladder Urothelial Carcinoma
Stage III Bladder Cancer AJCC v8

Interventions: Procedure: Biopsy of Bladder
Procedure: Biospecimen Collection
Drug: Cisplatin
Procedure: Computed Tomography
Procedure: Cystoscopy
Biological: Durvalumab
Other: Patient Observation
Drug: Gemcitabine Hydrochloride
Drug: Fluorouracil
Procedure: Magnetic Resonance Imaging
Drug: Mitomycin
Radiation: Radiation Therapy

First Posted Date: 2020-01-02

Last Posted Date: 2025-05-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 95

Registration Number: NCT04216290

Locations: 🇺🇸
Saint Luke's Cancer Institute - Boise, Boise, Idaho, United States
🇺🇸
Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
🇺🇸
Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States

and more 213 locations

Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma

Phase 1

Active, not recruiting

Conditions: Glioblastoma
Gliosarcoma
Newly Diagnosed

Interventions: Drug: Selinexor
Drug: Temozolomide
Radiation: Generic Radiation therapy (RT)
Other: Selective serotonin receptor (5-HT3) antagonists
Other: Olanzapine
Dietary Supplement: Salt tablets
Other: Anti-diarrheal

First Posted Date: 2020-01-02

Last Posted Date: 2025-06-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 11

Registration Number: NCT04216329

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer

Phase 3

Active, not recruiting

Conditions: Endometrial Endometrioid Adenocarcinoma
Stage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
Stage II Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8

Interventions: Procedure: Biospecimen Collection
Radiation: Brachytherapy
Procedure: Computed Tomography
Radiation: External Beam Radiation Therapy
Procedure: Magnetic Resonance Imaging
Other: Quality-of-Life Assessment
Biological: Pembrolizumab
Other: Questionnaire Administration
Procedure: X-Ray Imaging

First Posted Date: 2019-12-30

Last Posted Date: 2025-05-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 168

Registration Number: NCT04214067

Locations: 🇺🇸
AdventHealth Porter, Denver, Colorado, United States
🇵🇷
San Juan City Hospital, San Juan, Puerto Rico
🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States

and more 277 locations

Home Terms & Conditions Privacy Policy